

Sarah Lessire

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/808485/publications.pdf>

Version: 2024-02-01

31
papers

838
citations

643344

15
h-index

536525

29
g-index

33
all docs

33
docs citations

33
times ranked

1031
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. <i>Journal of Clinical Medicine</i> , 2022, 11, 1338.	1.0	4
2	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864899.	1.1	1
3	Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e48-e51.	0.7	11
4	Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. <i>Thrombosis Research</i> , 2021, 197, 20-23.	0.8	36
5	Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1585-1592.	0.7	2
6	The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. <i>American Journal of Medicine</i> , 2021, 134, 1295-1299.	0.6	16
7	Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. <i>Data in Brief</i> , 2020, 33, 106519.	0.5	19
8	Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Clinical Medicine</i> , 2020, 9, 2515.	1.0	17
9	Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3121-3124.	1.9	16
10	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 424.	1.0	4
11	Assessment of low plasma concentrations of apixaban in the periprocedural setting. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 394-402.	0.7	5
12	Evaluation of a new thromboplastin reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, international normalized ratio and extrinsic factor levels. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 650-660.	0.7	6
13	Assessment of the analytical performances and sample stability on ST Genesis system using the STG -DrugScreen application. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1273-1287.	1.9	43
14	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 250-261.	0.7	9
15	Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients. <i>Clinical Cardiology</i> , 2018, 41, 646-651.	0.7	6
16	Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 129-138.	0.7	22
17	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 209-219.	1.9	266
18	Evaluation of the DOAC-Stop-Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. <i>TH Open</i> , 2018, 02, e202-e209.	0.7	54

#	ARTICLE	IF	CITATIONS
19	Perioperative management of patients on direct oral anticoagulants. <i>Thrombosis Journal</i> , 2017, 15, 14.	0.9	92
20	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1275-1296.	1.4	10
21	An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. <i>Thrombosis Research</i> , 2017, 157, 29-37.	0.8	14
22	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, e24-e27.	0.6	15
23	Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 787-788.	1.1	5
24	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 41-50.	5.8	17
25	Estimation of dabigatran plasma concentrations in the perioperative setting. <i>Thrombosis and Haemostasis</i> , 2015, 113, 862-869.	1.8	53
26	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. <i>Thrombosis Research</i> , 2015, 136, 693-696.	0.8	28
27	Double-Lumen Tubes for Tracheostomized Patients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, e35-e36.	0.6	3
28	Erratum to "Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants". <i>BioMed Research International</i> , 2014, 2014, 1-1.	0.9	8
29	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	23
30	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	6
31	Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. <i>Thrombosis Research</i> , 2014, 133, 1074-1078.	0.8	23